ILLUMINA Business Summary

Illumina, Inc. (ILMN) utilizes a high-margin "razor-and-blade" revenue model, deriving over 75% of its annual turnover from sequencing consumables and recurring services tied to a global installed base of over 25,000 instruments. The business is structured around its core Sequencing segment—featuring the flagship NovaSeq X high-throughput series, NextSeq mid-range systems, and MiSeq benchtop units—alongside a specialized Microarray division and a burgeoning Multiomics portfolio following the January 2026 acquisition of SomaLogic. This strategic pivot into proteomics and AI-driven drug discovery, exemplified by the "Billion Cell Atlas" partnership with AstraZeneca and Merck, aims to offset research-market softness and geopolitical headwinds in China. Illumina maintains a dominant 65–75% share of the global next-generation sequencing (NGS) market, positioning itself as the primary infrastructure provider for clinical diagnostics and population genomics. It competes directly with Thermo Fisher Scientific, Agilent Technologies, Qiagen, and Pacific Biosciences; while it remains the undisputed leader in short-read sequencing, it is currently defending its moat against emerging long-read technologies and low-cost competitors in the Asia-Pacific region. Founded in 1998 by David R. Walt, John Stuelpnagel, Anthony J. Czarnik, Mark S. Chee, and Larry Bock, Illumina is currently led by CEO Jacob Thaysen, a former Agilent President who assumed leadership in 2023 to drive operational efficiency and margin recovery. The executive suite includes CTO Steve Barnard, the company’s inaugural scientist and architect of its core SBS chemistry, CFO Ankur Dhingra, and newly appointed Chief Medical Officer Eric D. Green, a genomics pioneer and former Director of the National Human Genome Research Institute (NHGRI). Strategy is further guided by Jakob Wedel, Chief Strategy and Corporate Development Officer, while CEO Thaysen currently serves as interim Chief Commercial Officer following recent leadership shifts. The company’s board of directors features prominent figures such as Keith Meister (Managing Partner of Corvex Management), former FDA Commissioner Scott Gottlieb, and Intuitive Surgical CEO Gary Guthart. Institutional stability is anchored by major shareholders including Capital World Investors, Vanguard, and BlackRock, who remain focused on the company’s 2026 revenue guidance of $4.5B–$4.6B and its transition toward a diversified multiomic ecosystem.